Industry Insights
According to this new report, the global cardiac biomarkers testing market is estimated to be valued at US$ 5.7 billion in the year 2027, growing at a CAGR of 8.5% in the period 2020 to 2027. Growth of the market is driven by the prevalence of cardiovascular cases, increasing geriatric population, higher precision and its non-invasiveness.
Cardiac biomarkers testing is used for diagnosis of various cardiovascular diseases such as cardiac ischemia, myocardial infarction, congestive heart failure, and acute coronary syndrome. Cardiac Biomarkers are basically protein molecules that are released into the bloodstream after heart damage or heart-stress. Hence measuring biomarkers usually serves as an important early step in diagnosing a heart attack.
The use of cardiac biomarkers in combination are widely applied in clinical diagnosis, risk stratification, and management of patients with or without cardiovascular diseases. One of the potent cardiac biomarker combinations is that of cTn and BNP which is quantitative markers of cardiac damage.
Report Scope
This report “Global Cardiac Biomarkers Testing Market [By Type - Creatine Kinase (CK-MB), Myoglobins, Ischemia Modified Albumin (IMA), Troponins & Natriuretic Peptides; By Application - Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure & Atherescelerosis; By Testing Location – POC Testing & Laboratory Testing; By Region- North America (The US), Europe (The UK & Germany) & Asia Pacific (China & Japan)] Market Outlook 2027” provides detailed analysis of the global cardiac biomarkers testing market from qualitative and quantitative outlooks during the forecast period across various regional markets. It also provides coverage on market dynamics with potential impact on the market during the forecast period and an in-depth analysis of the leading companies operating in the market.
Parameter Description
- Base year: 2016
- Forecast period: 2020 – 2027
- Market sizing: Revenue in US$ Billions & CAGR for the period 2016 to 2027
- Country coverage: The US, The UK, Germany, Japan & China
- Vendor scope: Roche Diagnostics, Abbott Laboratories, Siemens Healthcare, Becton, Dickinson and Company, Bio-Rad Laboratories & BioMerieux
- Report coverage: Revenue forecast, market share analysis, company analysis, competitive landscape, market growth drivers, market restraints, market trends and company profiles
Segments Covered
The report provides revenue forecasts for global, regional, and country levels. It also provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. For the purpose of research, the publisher has segmented global cardiac biomarkers testing market report on the basis of type, applications, testing location and geography.
Biomarkers Testing Type Outlook, Revenue (2018 – 2027E, US$ Billions)
- Creatine Kinase (CK-MB)
- Myoglobins
- Ischemia Modified Albumin (IMA)
- Troponins
- Natriuretic Peptides
Biomarkers Testing Application Outlook, Revenue (2018 – 2027E, US$ Billions)
- Acute Coronary Syndrome
- Myocardial Infarction
- Congestive Heart Failure
- Atherescelerosis
Biomarkers Testing Location Outlook, Revenue (2018 – 2027E, US$ Billions)
- POC Testing
- Laboratory Testing
Regional Outlook, Revenue (2018 – 2027E, US$ Billions)
- North America
- Europe
- Asia Pacific
Country Outlook, Revenue (2018 – 2027E, US$ Billions)
- The US
- The UK
- Germany
- Japan
- China
Vendors Outlook, Revenue (2015 – 2019, US$ Billions)
- Roche Diagnostics
- Abbott Laboratories
- Siemens Healthcare
- Becton, Dickinson, and Company
- Bio-Rad Laboratories
- BioMerieux
Target Audience
- Drug Manufacturers
- Chemical Suppliers
- End Users
- Research Professionals
- Healthcare Consultancies
- Regulatory Bodies
Key Questions Answered in the Report
- The historical market size of the cardiac biomarkers testing market in value terms in the period 2016 to 2019 in US$ Billions.
- Projected market growth in the forecasted period 2020 to 2027 with estimated revenue for each year in US$ Billions.
- Regional and country analysis of the cardiac biomarkers testing market is provided for the period 2018 to 2027.
- Market drivers, restraints and industry trends that has an impact on revenue.
- Profiling of major companies with a detailed analysis of their cardiac biomarkers testing products.
Table of Contents
1. Executive Summary2. Research Methodology
Executive Summary
Cardiac Biomarkers are the protein molecules that are released into the bloodstream after heart damage or heart-stress. It serves as a tool for the detection of various cardiovascular diseases (CVD) such as cardiac ischemia, myocardial infarction, congestive heart failure, and acute coronary syndrome (ACS). The common cardiac biomarkers that are tested for CVD include troponin, creatine kinase-muscle/brain (CK-MB), B-type natriuretic peptide (BNP), high-sensitivity C-reactive protein (hs-CRP), and many more. Creatine kinase was the first cardiac protein that has been widely used by doctors for the diagnosis of heart attacks. Recently, troponin has emerged as the more important blood protein for detecting heart cell damages.
There are a number of factors that impact the growth of the cardiac biomarkers market. Growth of the market is primarily attributed to the prevalence of cardiovascular cases, increasing geriatric population, higher precision and its non-invasiveness. With the rise in the number of cardiovascular disorders, there is a subsequent upsurge in demand for diagnostic and testing of various cardiovascular diseases, development and advancement in cardiac biomarkers. However, the market faces various challenges due to stringent regulatory compliance in the industry, high cost of treatment, and limited specificity associated with the use of individual cardiac markers for testing.
The report “Global Cardiac Biomarkers Testing Market [By Type - Creatine Kinase (CK-MB), Myoglobins, Ischemia Modified Albumin (IMA), Troponins & Natriuretic Peptides; By Application - Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure & Atherescelerosis; By Testing Location - POC Testing & Laboratory Testing; By Region- North America (The US), Europe (The UK & Germany) & Asia Pacific (China & Japan)] Market Outlook 2027” provides an in-depth analysis of the current scenario, detailed market outlook of the global cardiac biomarkers testing market. Future forecasts of the market overall and across various regional markets have been provided in the report until 2027. Furthermore, major industry players have been prudently analysed in the competitive landscape section of the report in order to provide key comparative insights.
Major industry players operating in the global cardiac biomarker testing market include Roche Diagnostics, Abbott Laboratories, Siemens Healthcare, Becton, Dickinson and Company, Bio-Rad Laboratories & BioMerieux, among others. These players are profiled herein based on attributes such as business overview, product segments and financial analysis. It also compiles the performance comparison of the aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global cardiac biomarker testing market.
Companies Mentioned
- Abbott Laboratories
- Becton, Dickinson and Company
- Bio-Rad Laboratories
- BioMerieux
- Roche Diagnostics
- Siemens Healthcare
Methodology
LOADING...